Celyad Oncology SA (CLYYF)
USD 0.53
(-22.44%)
USD 0.53
(-22.44%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -7.76 Million EUR | 52.13% |
| 2022 | -39.69 Million EUR | 26.46% |
| 2021 | -25.41 Million EUR | -5.73% |
| 2020 | -15.73 Million EUR | 11.87% |
| 2019 | -27.45 Million EUR | 26.54% |
| 2018 | -36.56 Million EUR | -124.21% |
| 2017 | -55.69 Million EUR | 23.87% |
| 2016 | -21.98 Million EUR | 21.39% |
| 2015 | -28.07 Million EUR | -54.32% |
| 2014 | -15.31 Million EUR | -63.51% |
| 2013 | -12.06 Million EUR | -2607.55% |
| 2012 | -12 Million EUR | 106.92% |
| 2011 | -6.36 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -2.85 Million EUR | 0.0% |
| 2023 Q2 | -5.42 Million EUR | 0.0% |
| 2023 Q4 | -4.46 Million EUR | 0.0% |
| 2022 Q4 | -12.01 Million EUR | 0.0% |
| 2022 Q2 | -7.6 Million EUR | -1.97% |
| 2022 Q1 | -7.45 Million EUR | 9.91% |
| 2022 FY | - EUR | 26.46% |
| 2021 Q4 | -8.27 Million EUR | -36.26% |
| 2021 Q2 | -6.33 Million EUR | 1.25% |
| 2021 Q3 | -6.07 Million EUR | 4.14% |
| 2021 Q1 | -6.41 Million EUR | 0.94% |
| 2021 FY | - EUR | -5.73% |
| 2020 Q2 | -15.24 Million EUR | 0.0% |
| 2020 FY | - EUR | 11.87% |
| 2020 Q4 | -6.47 Million EUR | -16.68% |
| 2020 Q3 | -5.55 Million EUR | 63.58% |
| 2019 FY | - EUR | 24.28% |
| 2019 Q1 | -6.62 Million EUR | 59.02% |
| 2019 Q2 | -16.32 Million EUR | -146.39% |
| 2019 Q4 | -16.29 Million EUR | 0.0% |
| 2018 Q2 | -15.16 Million EUR | -67.33% |
| 2018 FY | - EUR | 23.33% |
| 2018 Q4 | -16.17 Million EUR | 0.0% |
| 2018 Q1 | -9.06 Million EUR | 32.15% |
| 2017 FY | - EUR | -115.05% |
| 2017 Q4 | -13.35 Million EUR | 0.0% |
| 2017 Q2 | -11.79 Million EUR | 0.19% |
| 2017 Q1 | -11.82 Million EUR | -98.61% |
| 2016 FY | - EUR | 21.42% |
| 2016 Q2 | -16.58 Million EUR | -201.78% |
| 2016 Q4 | -5.95 Million EUR | 0.0% |
| 2016 Q1 | -5.49 Million EUR | 59.9% |
| 2015 Q4 | -13.7 Million EUR | -95.95% |
| 2015 FY | - EUR | -79.81% |
| 2015 Q3 | -6.99 Million EUR | 52.43% |
| 2015 Q2 | -14.7 Million EUR | -110.21% |
| 2015 Q1 | -6.99 Million EUR | 29.78% |
| 2014 FY | - EUR | -41.02% |
| 2014 Q1 | -3.89 Million EUR | 40.95% |
| 2014 Q4 | -9.96 Million EUR | -156.08% |
| 2014 Q2 | -6 Million EUR | -54.28% |
| 2014 Q3 | -3.89 Million EUR | 35.18% |
| 2013 Q1 | -2.75 Million EUR | 0.0% |
| 2013 Q2 | -5.56 Million EUR | -101.56% |
| 2013 Q3 | -2.75 Million EUR | 50.39% |
| 2013 Q4 | -6.58 Million EUR | -138.79% |
| 2013 FY | - EUR | -776.66% |
| 2012 Q3 | -314.68 Thousand EUR | 0.0% |
| 2012 Q2 | -314.68 Thousand EUR | 0.0% |
| 2012 Q1 | -314.68 Thousand EUR | 0.0% |
| 2012 FY | - EUR | 80.37% |
| 2012 Q4 | -2.75 Million EUR | -776.66% |
| 2011 Q1 | -1.6 Million EUR | 0.0% |
| 2011 Q2 | -1.6 Million EUR | 0.0% |
| 2011 Q3 | -1.6 Million EUR | 0.0% |
| 2011 Q4 | -314.68 Thousand EUR | 80.37% |
| 2011 FY | - EUR | 0.0% |
| 2010 Q4 | -1.6 Million EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Capstone Therapeutics Corp. | -1.74 Million USD | -343.6% |
| Skye Bioscience, Inc. | -13.54 Million USD | 42.698% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 108.255% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 1571.846% |
| Qrons Inc. | -40.08 Thousand USD | -19268.279% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -2013.986% |
| Adynxx, Inc. | - USD | Infinity% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -99.855% |
| BioStem Technologies, Inc. | -7.55 Million USD | -2.772% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -728.54% |
| CSL Limited | 4.78 Billion USD | 100.162% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 85.972% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 55.308% |
| Rebus Holdings, Inc. | -951 Thousand USD | -716.299% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -1127.534% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 51.083% |
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 89.072% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | -30.935% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -3146.08% |
| SQZ Biotechnologies Company | -64.14 Million USD | 87.897% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -193.558% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -405.388% |
| Mesoblast Limited | -62.38 Million USD | 87.557% |
| Marizyme, Inc. | -34.28 Million USD | 77.355% |
| Genus plc | 73.7 Million USD | 110.533% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | -17.416% |
| Pharming Group N.V. | 9.87 Million USD | 178.597% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -421.913% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -118.861% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 11.503% |
| ContraFect Corporation | -64.99 Million USD | 88.057% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | -71.513% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -453.785% |
| IMV Inc. | -35.52 Million USD | 78.147% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -234.062% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -1398.516% |
| ONE Bio Corp. | 13.61 Million USD | 157.026% |
| Accustem Sciences Inc. | -3.74 Million USD | -107.211% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 83.903% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -512.643% |
| Q BioMed Inc. | -617.62 Thousand USD | -1156.905% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 317.329% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -239.813% |
| Biomind Labs Inc. | -1.03 Million USD | -650.375% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 80.415% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -168.4% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | -8.402% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 115552.112% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -30952.0% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -210.276% |
| GB Sciences, Inc. | -1.41 Million USD | -446.734% |
| Alpha Cognition Inc. | -9.7 Million USD | 20.015% |
| HST Global, Inc. | -5303.00 USD | -146288.837% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -277.394% |
| Halberd Corporation | -74.27 Thousand USD | -10351.137% |
| Enzolytics Inc. | -2.12 Million USD | -265.829% |
| Agentix Corp. | -1.37 Million USD | -465.917% |
| Resverlogix Corp. | -11.74 Million USD | 33.887% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -153.443% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -216.02 Million USD | 96.406% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 737.88% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 187.68% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -417.911% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 2149.128% |
| AVAX Technologies, Inc. | -6.11 Million USD | -26.999% |
| Zenith Capital Corp. | -8.6 Million USD | 9.795% |
| Genscript Biotech Corporation | -248.71 Million USD | 96.879% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -44461.162% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -217.316% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -4310.185% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -304.131% |
| Kadimastem Ltd | -2.62 Million USD | -195.803% |
| Helix BioMedix, Inc. | -1.04 Million USD | -641.939% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -4186.866% |
| LadRx Corporation | 412.28 Thousand USD | 1982.93% |
| Cell Source, Inc. | -4.27 Million USD | -81.696% |
| Regen BioPharma, Inc. | 1.46 Million USD | 629.552% |
| NovAccess Global Inc. | -1.03 Million USD | -650.195% |
| Affymax, Inc. | -14.29 Million USD | 45.694% |
| Itoco Inc. | -1.86 Million USD | -315.357% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -1944.94% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -595.609% |
| Mobile Lads Corp. | -2.24 Million USD | -246.383% |
| CytoDyn Inc. | -18.02 Million USD | 56.942% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -9722.976% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -63380.252% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -1498.384% |
| SYBLEU INC | -141.57 Thousand USD | -5383.468% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -630.972% |
| International Stem Cell Corporation | 202 Thousand USD | 3943.069% |
| Bioxytran, Inc. | -3.82 Million USD | -103.212% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -14647.34% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -215.321% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 78.357% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -17151.111% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -183.528% |
| Neutra Corp. | -181.24 Thousand USD | -4183.105% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 61.491% |
| PureTech Health plc | -11.62 Million USD | 33.233% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 61.489% |
| IXICO plc | -707 Thousand USD | -998.02% |
| IntelGenx Technologies Corp. | -7.68 Million USD | -1.015% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 83.943% |
| CSL Limited | 4.73 Billion USD | 100.164% |
| Cellectis S.A. | -92.63 Million USD | 91.62% |